These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7914235)

  • 41. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.
    Goebel FD; Mannhalter JW; Belshe RB; Eibl MM; Grob PJ; de Gruttola V; Griffiths PD; Erfle V; Kunschak M; Engl W
    AIDS; 1999 Aug; 13(12):1461-8. PubMed ID: 10465068
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
    Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
    J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
    Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
    Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
    Wecker M; Gilbert P; Russell N; Hural J; Allen M; Pensiero M; Chulay J; Chiu YL; Abdool Karim SS; Burke DS; ;
    Clin Vaccine Immunol; 2012 Oct; 19(10):1651-60. PubMed ID: 22914365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
    Launay O; Durier C; Desaint C; Silbermann B; Jackson A; Pialoux G; Bonnet B; Poizot-Martin I; Gonzalez-Canali G; Cuzin L; Figuereido S; Surenaud M; Ben Hamouda N; Gahery H; Choppin J; Salmon D; Guérin C; Bourgault Villada I; Guillet JG;
    PLoS One; 2007 Aug; 2(8):e725. PubMed ID: 17712402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
    Autran B; Murphy RL; Costagliola D; Tubiana R; Clotet B; Gatell J; Staszewski S; Wincker N; Assoumou L; El-Habib R; Calvez V; Walker B; Katlama C;
    AIDS; 2008 Jul; 22(11):1313-22. PubMed ID: 18580611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.
    Rockstroh JK; Asmuth D; Pantaleo G; Clotet B; Podzamczer D; van Lunzen J; Arastéh K; Mitsuyasu R; Peters B; Silvia N; Jolliffe D; Ökvist M; Krogsgaard K; Sommerfelt MA
    PLoS One; 2019; 14(1):e0210965. PubMed ID: 30699178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.
    Ensoli F; Cafaro A; Casabianca A; Tripiciano A; Bellino S; Longo O; Francavilla V; Picconi O; Sgadari C; Moretti S; Cossut MR; Arancio A; Orlandi C; Sernicola L; Maggiorella MT; Paniccia G; Mussini C; Lazzarin A; Sighinolfi L; Palamara G; Gori A; Angarano G; Di Pietro M; Galli M; Mercurio VS; Castelli F; Di Perri G; Monini P; Magnani M; Garaci E; Ensoli B
    Retrovirology; 2015 Apr; 12():33. PubMed ID: 25924841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
    Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
    Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.
    de Jong W; Aerts J; Allard S; Brander C; Buyze J; Florence E; van Gorp E; Vanham G; Leal L; Mothe B; Thielemans K; Plana M; Garcia F; Gruters R;
    Trials; 2019 Jun; 20(1):361. PubMed ID: 31208472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
    Mehendale S; van Lunzen J; Clumeck N; Rockstroh J; Vets E; Johnson PR; Anklesaria P; Barin B; Boaz M; Kochhar S; Lehrman J; Schmidt C; Peeters M; Schwarze-Zander C; Kabamba K; Glaunsinger T; Sahay S; Thakar M; Paranjape R; Gilmour J; Excler JL; Fast P; Heald AE
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):873-80. PubMed ID: 18544020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
    Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES
    AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.
    Emery S; Workman C; Puls RL; Bloch M; Baker D; Bodsworth N; Anderson J; Crowe SM; French MA; Hoy J; Aichelburg A; Ward LD; Boyle DB; Law MG; Kelleher AD; Cooper DA
    Hum Vaccin; 2005; 1(6):232-8. PubMed ID: 17012863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
    Guardo AC; Gómez CE; Díaz-Brito V; Pich J; Arnaiz JA; Perdiguero B; García-Arriaza J; González N; Sorzano COS; Jiménez L; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; Alcamí J; Esteban M; López Bernaldo de Quirós JC; García F; Plana M;
    PLoS One; 2017; 12(10):e0186602. PubMed ID: 29065142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.